Key facts
- It has raised $73.5M; the latest was Later Stage VC ($61.0M) in Jan 2026.
- Notable investors include HSG (Hong Kong), Northern Light Venture Capital, Pfizer Ventures, HSG, Apricot Capital (Shanghai) — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Vibrant Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vibrant Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vibrant Therapeutics
Developer of an AI-driven smart macromolecular drug development platform intended to serve the industry. The company focuses on fields that face significant unmet medical needs, such as AI in tumour immunotherapy, and is committed to building a macromolecule drug development platform to enhance the quality and efficiency of macromolecule drug research and development.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Employees
- 5
- Website
- vibrantx.com/
- Ownership
- Privately Held (backing)
Vibrant Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vibrant Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vibrant Therapeutics in its N-PORT filings yet. We sweep new filings monthly.